FindMyKOL
Clinical trialNCT05488431RecruitingPhase 2Interventional

Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)

NCT05488431 is a phase 2 interventional trial sponsored by Priscilla Hsue, MD. As of 21 Nov 2026, it is recruiting participants. It studies Bempedoic acid in Atherosclerosis, Cardiovascular Diseases and 2 more conditions. The registry lists an enrollment of 121 participants at 3 sites in 1 country. The registry lists a start date of 1 Mar 2023 and a primary completion date of 1 Mar 2028. 4 of its registered investigators have a FindMyKOL profile.

SponsorPriscilla Hsue, MDEnrollment121AtherosclerosisCardiovascular DiseasesDyslipidemiasHIV Infections
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT05488431
FieldValue
Registry IDNCT05488431
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorPriscilla Hsue, MD
Enrollment121
Registered sites3
Countries1
ConditionsAtherosclerosis, Cardiovascular Diseases, Dyslipidemias and HIV Infections
DrugsBempedoic acid
Start1 Mar 2023
Primary completion1 Mar 2028
Study completion1 Mar 2028
Last update posted17 Dec 2025

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET/CT, lipids, inflammation, immune activation, cardiometabolic indices, and non-calcified plaque (NCP) in the coronary arteries (assessed by coronary CT angiography, CCTA). This trial will be enrolled at UCSF and UCLA. Collaborators at Massachusetts General Hospital (MGH) will serve as the core facility for imaging.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States2 sites, 2 recruiting
  • Ucla Center for Clinical Aids Research and Education (care)

    Los Angeles

    Judith Currier, MDPriscilla Hsue, MD →
    Recruiting
  • San Francisco General Hospital

    San Francisco

    Adam Spivak, MDAhmed Tawakol, MDBorek Foldyna, MDJohn Kornak, MDMichael Lu, MDMiguel Pampaloni, MDPriscilla Hsue, MD →Steven Deeks, MDYoojin Lee, MD
    Recruiting
Texas, United States1 site, 1 recruiting
  • Ut Health Houston

    Houston

    Jordan Lake, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 2 sites, 2 recruitingCA2NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 site, 1 recruitingTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT05488431

Each answer restates registry values shown on this page.

What is NCT05488431?

NCT05488431 is a phase 2 interventional trial sponsored by Priscilla Hsue, MD. It studies Bempedoic acid in Atherosclerosis, Cardiovascular Diseases and 2 more conditions.

Is NCT05488431 recruiting?

As of 21 Nov 2026, it is recruiting participants. 3 of its 3 sites list their own status as recruiting.

Who leads NCT05488431?

The registry names Priscilla Hsue, MD (principal investigator, University of California, Los Angeles) as the overall official.

Where does NCT05488431 run?

The registry lists 3 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT05488431 study?

The registered drug and biological interventions are Bempedoic acid.

When is NCT05488431 expected to complete?

The registry lists a primary completion date of 1 Mar 2028 and a study completion date of 1 Mar 2028. The sponsor last updated the record on 17 Dec 2025.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.